Iovance

Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May…

SAN CARLOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Iovance…

SAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance…

SAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA)…

31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4) 42% of Responses Lasted for 24+ Months SITC Update and KOL Panel Webcast…